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The histopathological hallmark of Parkinson’s disease 
(PD) and dementia with Lewy bodies (DLB) is the 
occurrence of insoluble fibrillary aggregates known as 
Lewy bodies, in which phosphorylated α-synuclein is a 
major component. Phosphorylated α-synuclein is also a 
constituent protein of glial cytoplasmic inclusions in 
multiple system atrophy (MSA). Thus, PD, DLB and 
MSA give rise to a disease concept of synucleinopathy. 
Macroautophagy (referred to as autophagy hereafter) is 
a highly conserved degradation pathway whereby cyto-
solic components as well as aberrant proteins are 
sequestered within double-membraned vesicles, known 
as autophagosomes. Autophagy consists of three pro-
cesses: initiation of autophagy, formation of auto-
phagosomes, and degradation of abnormal proteins after 
fusion with lysosomes. Each process is meticulously 
controlled and failure of any step of autophagy can lead 
to accumulation of abnormal proteins, including α-
synuclein, in neurons, resulting in neuronal cell death 
[1]. 
Dysfunction of autophagy is now acknowledged as one 
of the features in several neurodegenerative disorders 
such as Alzheimer’s disease, amyotrophic lateral scre-
losis, Huntington’s disease and synucleinopathies. 
Indeed, in postmortem brains of patients with PD and 
DLB, upstream autophagosomal proteins (UNC-51-like 
kinase 1/2 (ULK1/2), Beclin1, vacuolar protein sorting-
associated protein 34 (VPS34), and autophagy/beclin1 
regulator 1 (AMBRA1)), which initiate autophagy and 
form autophagosomes, were found to be involved in 
Lewy body formation. Immunoblotting using frac-
tionated brain lysates from DLB patients showed 
Beclin1 and VPS34 in soluble and insoluble smear 
bands of phosphorylated α-synuclein. Much stronger 
bands of ULK1 and ULK2 were found in the soluble 
fraction of DLB patients. We also investigated the 
alteration of autophagy in a cellular model of PD, 
demonstrating chronological upregulation of ULK1, 
ULK2, Beclin1 and VPS34 in response to accumulation 
of α-synuclein whereas in the brains of PD and DLB, 
increase of these upstream autophagosomal proteins 
was only partial [2]. Moreover, in surface plasmon 
resonance analysis, mutant α-synuclein had nine-times 
higher affinity for AMBRA1 compared with wild type 
α-synuclein, suggesting sequestering AMBRA1 from its 
original position [3]. Investigating the downstream part 
of the autophagy pathway, we were also able to  demon- 








strate dysfunction indicated by alteration of micro-
tubule-associated protein 1 light chain 3 (LC3) and γ-
aminobutyric type A receptor associated proteins 
(GABARAPs), key regulators in this part of the 
autophagy pathway [4]. Taken together, our findings 
suggest dysregulation in various steps of autophagy in 
the pathogenesis of PD and DLB. However, because 
these results are based on in-vitro or postmortem 
studies, it has not been clarified whether impairment of 
autophagy represents a fundamental aspect of PD, or is 
the final stage of dysregulation resulting from a long 
neurodegenerative process. Therefore, in order to 
improve our understanding of altered autophagy in the 
early stage of PD, we then studied basal activity of 
autophagy using peripheral blood mononuclear cells 
(PBMCs) of patients with PD and control subjects. The 
whole-transcriptome assay revealed down-regulation of 
mRNAs for six core regulators of autophagy. Protein 
levels of ULK1, Beclin1 and AMBRA1 were increased 
with negative feedback on mRNA expression for these 
proteins in PD. There was significant correlation bet-
ween these protein levels and α-synuclein in PBMCs. 
The expression level of the oligomeric form of α-
synuclein in PBMCs paralleled the clinical severity and 
degeneration of cardiac sympathetic nerves in PD [5]. 
Collectively, our findings indicate that impairment of 
autophagy, which can occur at the various steps of 
autophagy, can occur during the disease process of PD 
and may precede the clinical manifestation of disease. 
Next, we explored the alteration of autophagy in 
postmortem brains of MSA. Although immunohisto-
chemical and biochemical analyses revealed different 
patterns of impaired autophagy between Lewy body 
disease and MSA, both disorders shared dysfunction of 
the autophagosome closure process [4, 6].    
Dysfunction of protein degradation pathways is 
implicated in the formation mechanism of Lewy bodies 
and glial cytoplasmic inclusions. Kim et al. demons-
trated that lysosomal degradation was impaired with 
aging, and genetic and pharmacological anti-aging 
manipulations alleviated propagation of α-synuclein in 
Caenorhabditis elegans models [7]. However, little is 
known about whether basal activity of autophagy could 
affect progression of disease among individuals with 
synucleinopathies, especially MSA. It would be of great 
interest to compare alteration of autophagy between 
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tions, and with minimal and severe pathological change. 
Investigation of differences among individuals in the 
activity of autophagy might enable us to understand the 
variable severity of neurodegeneration in synucleino-
pathies, leading to the development of future therapeutic 
strategies to delay accumulation of abnormal α-
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